Department of Economics and Business Economics

Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

DOI

  • Fiona J Charlson, Department of Global Health, Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA.
  • ,
  • Alize J Ferrari, Department of Global Health, Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA.
  • ,
  • Damian F Santomauro, Department of Global Health, Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA.
  • ,
  • Sandra Diminic, Queensland Centre for Schizophrenia Mental Health Research, The Park, Centre for Mental Health, Wacol, Australia.
  • ,
  • Emily Stockings, National Drug and Alcohol Research Centre (NDARC), University of New South Wales, Randwick, Australia.
  • ,
  • James G Scott, Queensland Centre for Schizophrenia Mental Health Research, The Park, Centre for Mental Health, Wacol, Australia., Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Herston, QLD, Australia. j.kesby@uq.edu.au., The University of Queensland, UQ Centre for Clinical Research, Herston, Queensland 4029, Australia; Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, QLD 4076, Australia; Metro North Mental Health, Royal Brisbane and Women's Hospital, Herston, Queensland 4029, Australia. Electronic address: james.scott@health.qld.gov.au.
  • ,
  • John J McGrath
  • Harvey A Whiteford, Department of Global Health, Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA.

Introduction: The global burden of disease (GBD) studies have derived detailed and comparable epidemiological and burden of disease estimates for schizophrenia. We report GBD 2016 estimates of schizophrenia prevalence and burden of disease with disaggregation by age, sex, year, and for all countries.

Method: We conducted a systematic review to identify studies reporting the prevalence, incidence, remission, and/or excess mortality associated with schizophrenia. Reported estimates which met our inclusion criteria were entered into a Bayesian meta-regression tool used in GBD 2016 to derive prevalence for 20 age groups, 7 super-regions, 21 regions, and 195 countries and territories. Burden of disease estimates were derived for acute and residual states of schizophrenia by multiplying the age-, sex-, year-, and location-specific prevalence by 2 disability weights representative of the disability experienced during these states.

Findings: The systematic review found a total of 129 individual data sources. The global age-standardized point prevalence of schizophrenia in 2016 was estimated to be 0.28% (95% uncertainty interval [UI]: 0.24-0.31). No sex differences were observed in prevalence. Age-standardized point prevalence rates did not vary widely across countries or regions. Globally, prevalent cases rose from 13.1 (95% UI: 11.6-14.8) million in 1990 to 20.9 (95% UI: 18.5-23.4) million cases in 2016. Schizophrenia contributes 13.4 (95% UI: 9.9-16.7) million years of life lived with disability to burden of disease globally.

Conclusion: Although schizophrenia is a low prevalence disorder, the burden of disease is substantial. Our modeling suggests that significant population growth and aging has led to a large and increasing disease burden attributable to schizophrenia, particularly for middle income countries.

Original languageEnglish
JournalSchizophrenia Bulletin
Volume44
Issue6
ISSN0586-7614
DOIs
Publication statusPublished - 2018

See relations at Aarhus University Citationformats

ID: 127160316